Drug intelligence / Profile preview

bms-275183

Development stage: Phase 2
Lead developer: Bristol Myers Squibb
Modality: Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

BMS-275183 is an orally active, small molecule taxane analogue developed by Bristol Myers Squibb for cancer treatment. It acts as an inhibitor of tubulin polymerization, similar to other taxanes like paclitaxel, thereby disrupting microtubule dynamics and inhibiting cell division in tumor cells. Unlike some other taxanes, BMS-275183 is not a substrate for P-glycoprotein, suggesting potential utility against multi-drug resistant tumors. The drug was investigated primarily for non-small cell lung cancer (NSCLC) and other solid tumors in phase I and II clinical trials but its development has been discontinued[1][2][3][5][6][7].

Other names: 14C BMS-275183

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on bms-275183.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bms-275183.

Explore the full profile